GSK Plc (NYSE:GSK) stock rose Tuesday after the British drugmaker reported better-than-expected second-quarter results.
Launches $2.52 Billion Cost-Savings Program
GSK said its new Accelerate Growth program targets 1.9 billion pounds ($2.52 billion) in annual savings by 2029, with expected implementation costs of 2.4 billion pounds.
The company said most of the savings will be reinvested to support growth, while a portion will be used to improve margins and profitability during the dolutegravir loss-of-exclusivity period from 2028 through 2030.
“We believe these plans, together with continued disciplined capital allocation, will drive strong operational performance and shareholder returns over the next five years, delivering our 2031 sales outlook and accelerated long-term growth,” CEO Luke Miels said.
